Hijacking of the ubiquitin/proteasome pathway by the hiv auxiliary proteins

Viruses

Volumn 9, Issue 11, 2017, Pages

  Seissler, Tanja ^a   Marquet, Roland ^a   Paillart, Jean Christophe ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

APOBEC; BST2 Tetherin; HIV; March8; Proteasome; Restriction factors; SAMHD1; TRIM5 ; Ubiquitin

Indexed keywords

CAPSID PROTEIN; CD4 ANTIGEN; CLATHRIN; CULLIN; DEUBIQUITINASE; ESCRT PROTEIN; GAG PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HOLOENZYME; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE; INTERCELLULAR ADHESION MOLECULE 1; POL PROTEIN; PROTEASOME; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VPU PROTEIN; CARRIER PROTEIN; MARCH8 PROTEIN, HUMAN; PROTEIN BINDING; TRIM5 PROTEIN, HUMAN; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVESICULAR BODY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; REVIEW; VIRUS CORE; VIRUS ENTRY; VIRUS INFECTION; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSCRIPTION; HOST PATHOGEN INTERACTION; METABOLISM; PATHOPHYSIOLOGY; UBIQUITINATION; VIROLOGY;

CARRIER PROTEINS; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 85033451147     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v9110322     Document Type: Review

References (176)

1. Bailey-Elkin, B. A.; Knaap, R. C. M.; Kikkert, M.; Mark, B. L. Structure and function of viral deubiquitinating enzymes. J. Mol. Biol. 2017.
2. Roos-Mattjus, P.; Sistonen, L. The ubiquitin-proteasome pathway. Ann. Med. 2004, 36, 285–295.
3. Clague, M. J.; Urbé, S. Ubiquitin: Same molecule, different degradation pathways. Cell 2010, 143, 682–685.
4. Davis, M. E.; Gack, M. U. Ubiquitination in the antiviral immune response. Virology 2015, 479–480, 52–65.
5. Petroski, M. D.; Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6, 9–20.
6. Hershko, A.; Heller, H.; Elias, S.; Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 1983, 258, 8206–8214.
7. Scheffner, M.; Nuber, U.; Huibregtse, J. M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 1995, 373, 81–83.
8. Gregori, L.; Poosch, M. S.; Cousins, G.; Chau, V. A uniform isopeptide-linked multiubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis. J. Biol. Chem. 1990, 265, 8354–8357.
9. Chau, V.; Tobias, J. W.; Bachmair, A.; Marriott, D.; Ecker, D. J.; Gonda, D. K.; Varshavsky, A. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989, 243, 1576–1583.
10. Collins, G. A.; Goldberg, A. L. The logic of the 26S proteasome. Cell 2017, 169, 792–806.
11. Matthews, W.; Driscoll, J.; Tanaka, K.; Ichihara, A.; Goldberg, A. L. Involvement of the proteasome in various degradative processes in mammalian cells. Proc. Natl. Acad. Sci. USA 1989, 86, 2597–2601.
12. Bashore, C.; Dambacher, C. M.; Goodall, E. A.; Matyskiela, M. E.; Lander, G. C.; Martin, A. Ubp6 deubiquitinase controls conformational dynamics and substrate degradation of the 26S proteasome. Nat. Struct. Mol. Biol. 2015, 22, 712–719.
13. Hamazaki, J.; Hirayama, S.; Murata, S. Redundant roles of rpn10 and rpn13 in recognition of ubiquitinated proteins and cellular homeostasis. PLoS Genet. 2015, 11, e1005401.
14. Harshbarger, W.; Miller, C.; Diedrich, C.; Sacchettini, J. Crystal structure of the human 20S proteasome in complex with carfilzomib. Structure 2015, 23, 418–424.
15. Hurley, J. H.; Emr, S. D. The Escrt complexes: Structure and mechanism of a membrane-trafficking network. Annu. Rev. Biophys. Biomol. Struct. 2006, 35, 277–298.
16. Lauwers, E.; Jacob, C.; André, B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J. Cell Biol. 2009, 185, 493–502.
17. Katzmann, D. J.; Babst, M.; Emr, S. D. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 2001, 106, 145–155.
18. Calistri, A.; Munegato, D.; Carli, I.; Parolin, C.; Palù, G. The ubiquitin-conjugating system: Multiple roles in viral replication and infection. Cells 2014, 3, 386–417.
19. Randow, F.; Lehner, P. J. Viral avoidance and exploitation of the ubiquitin system. Nat. Cell Biol. 2009, 11, 527–534.
20. Biard-Piechaczyk, M.; Borel, S.; Espert, L.; de Bettignies, G.; Coux, O. HIV-1, ubiquitin and ubiquitin-like proteins: The dialectic interactions of a virus with a sophisticated network of post-translational modifications. Biol. Cell 2012, 104, 165–187.
21. Ott, D. E.; Coren, L. V.; Copeland, T. D.; Kane, B. P.; Johnson, D. G.; Sowder, R. C.; Yoshinaka, Y.; Oroszlan, S.; Arthur, L. O.; Henderson, L. E. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of moloney murine leukemia virus. J. Virol. 1998, 72, 2962–2968.
22. Gottwein, E.; Jäger, S.; Habermann, A.; Kräusslich, H. -G. Cumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 gag cause a late budding defect. J. Virol. 2006, 80, 6267–6275.
23. Garrus, J. E.; von Schwedler, U. K.; Pornillos, O. W.; Morham, S. G.; Zavitz, K. H.; Wang, H. E.; Wettstein, D. A.; Stray, K. M.; Côté, M.; Rich, R. L.; et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107, 55–65.
24. Ott, D. E.; Coren, L. V.; Chertova, E. N.; Gagliardi, T. D.; Schubert, U. Ubiquitination of HIV-1 and MuLV Gag. Virology 2000, 278, 111–121.
25. Brès, V.; Kiernan, R. E.; Linares, L. K.; Chable-Bessia, C.; Plechakova, O.; Tréand, C.; Emiliani, S.; Peloponese, J. -M.; Jeang, K. -T.; Coux, O.; et al. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat. Cell Biol. 2003, 5, 754–761.
26. Faust, T. B.; Li, Y.; Jang, G. M.; Johnson, J. R.; Yang, S.; Weiss, A.; Krogan, N. J.; Frankel, A. D. PJA2 ubiquitinates the HIV-1 Tat protein with atypical chain linkages to activate viral transcription. Sci. Rep. 2017, 7, 45394.
27. Fu, B.; Wang, L.; Ding, H.; Schwamborn, J. C.; Li, S.; Dorf, M. E. TRIM32 senses and restricts influenza a virus by ubiquitination of PB1 polymerase. PLoS Pathog. 2015, 11.
28. Van Tol, S.; Hage, A.; Giraldo, M. I.; Bharaj, P.; Rajsbaum, R. The TRIMendous role of TRIMs in virus-host interactions. Vaccines 2017, 5.
29. Horan, K. A.; Hansen, K.; Jakobsen, M. R.; Holm, C. K.; Søby, S.; Unterholzner, L.; Thompson, M.; West, J. A.; Iversen, M. B.; Rasmussen, S. B.; et al. Proteasomal degradation of herpes simplex virus capsids in macrophages releases DNA to the cytosol for recognition by DNA sensors. J. Immunol. 2013, 190, 2311–2319.
30. Reszka, N.; Zhou, C.; Song, B.; Sodroski, J. G.; Knipe, D. M. Simian TRIM5_ proteins reduce replication of herpes simplex virus. Virology 2010, 398, 243–250.
31. Scheffner, M.; Werness, B. A.; Huibregtse, J. M.; Levine, A. J.; Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63, 1129–1136.
32. Scheffner, M.; Huibregtse, J. M.; Vierstra, R. D.; Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75, 495–505.
33. Graff, J. W.; Ettayebi, K.; Hardy, M. E. Rotavirus NSP1 inhibits NF_B activation by inducing proteasome-dependent degradation of _-TrCP: A novel mechanism of IFN antagonism. PLoS Pathog. 2009, 5.
34. Morelli, M.; Dennis, A. F.; Patton, J. T. Putative E3 ubiquitin ligase of human rotavirus inhibits NF-_B activation by using molecular mimicry to Target _-TrCP. mBio 2015, 6.
35. Ishido, S.; Wang, C.; Lee, B. S.; Cohen, G. B.; Jung, J. U. Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 2000, 74, 5300–5309.
36. Lorenzo, M. E.; Jung, J. U.; Ploegh, H. L. Kaposi’s sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. J. Virol. 2002, 76, 5522–5531.
37. Chelbi-Alix, M. K.; de Thé, H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 1999, 18, 935–941.
38. Everett, R. D.; Rechter, S.; Papior, P.; Tavalai, N.; Stamminger, T.; Orr, A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 2006, 80, 7995–8005.
39. Setz, C.; Friedrich, M.; Rauch, P.; Fraedrich, K.; Matthaei, A.; Traxdorf, M.; Schubert, U. Inhibitors of deubiquitinating enzymes block HIV-1 replication and augment the presentation of Gag-derived MHC-I epitopes. Viruses 2017, 9.
40. Schubert, U.; Ott, D. E.; Chertova, E. N.; Welker, R.; Tessmer, U.; Princiotta, M. F.; Bennink, J. R.; Krausslich, H. G.; Yewdell, J. W. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 2000, 97, 13057–13062.
41. Ott, D. E.; Coren, L. V.; Sowder, R. C.; Adams, J.; Schubert, U. Retroviruses have differing requirements for proteasome function in the budding process. J. Virol. 2003, 77, 3384–3393.
42. Yu, L.; Mohanram, V.; Simonson, O. E.; Smith, C. I. E.; Spetz, A. -L.; Mohamed, A. J. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. Biochem. Biophys. Res. Commun. 2009, 385, 100–105.
43. Frankel, A. D.; Young, J. A. HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67, 1–25.
44. Freed, E. O. HIV-1 replication. Somat. Cell Mol. Genet. 2001, 26, 13–33.
45. Azevedo-Pereira, J. M.; Santos-Costa, Q. HIV interaction with human host: HIV-2 as a model of a less virulent infection. AIDS Rev. 2016, 18, 44–53.
46. Jakobsdottir, G. M.; Iliopoulou, M.; Nolan, R.; Alvarez, L.; Compton, A. A.; Padilla-Parra, S. On the whereabouts of HIV-1 cellular entry and its fusion ports. Trends Mol. Med. 2017.
47. Cimarelli, A.; Darlix, J. -L. HIV-1 reverse transcription. Methods Mol. Biol. 2014, 1087, 55–70.
48. Craigie, R.; Bushman, F. D. HIV DNA integration. Cold Spring Harb. Perspect. Med. 2012, 2, a006890.
49. Sundquist, W. I.; Kräusslich, H. -G. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2012, 2, a006924.
50. Usami, Y.; Wu, Y.; Göttlinger, H. G. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 2015, 526, 218–223.
51. Rosa, A.; Chande, A.; Ziglio, S.; de Sanctis, V.; Bertorelli, R.; Goh, S. L.; McCauley, S. M.; Nowosielska, A.; Antonarakis, S. E.; Luban, J.; et al. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 2015, 526, 212–217.
52. Compton, A. A.; Bruel, T.; Porrot, F.; Mallet, A.; Sachse, M.; Euvrard, M.; Liang, C.; Casartelli, N.; Schwartz, O. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 2014, 16, 736–747.
53. Lu, J.; Pan, Q.; Rong, L.; Liu, S. -L.; Liang, C. The IFITM proteins inhibit HIV-1 infection. J. Virol. 2011, 85, 2126–2137.
54. Wang, Y.; Pan, Q.; Ding, S.; Wang, Z.; Yu, J.; Finzi, A.; Liu, S. -L.; Liang, C. The V3 loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity. J. Virol. 2017, 91, e02441-16.
55. Tartour, K.; Appourchaux, R.; Gaillard, J.; Nguyen, X. -N.; Durand, S.; Turpin, J.; Beaumont, E.; Roch, E.; Berger, G.; Mahieux, R.; et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology 2014, 11, 103.
56. Yu, J.; Li, M.; Wilkins, J.; Ding, S.; Swartz, T. H.; Esposito, A. M.; Zheng, Y. -M.; Freed, E. O.; Liang, C.; Chen, B. K.; et al. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep. 2015, 13, 145–156.
57. Foster, T. L.; Wilson, H.; Iyer, S. S.; Coss, K.; Doores, K.; Smith, S.; Kellam, P.; Finzi, A.; Borrow, P.; Hahn, B. H.; et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 2016, 20, 429–442.
58. Roa, A.; Hayashi, F.; Yang, Y.; Lienlaf, M.; Zhou, J.; Shi, J.; Watanabe, S.; Kigawa, T.; Yokoyama, S.; Aiken, C.; et al. RING domain mutations uncouple TRIM5_ restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J. Virol. 2012, 86, 1717–1727.
59. Stremlau, M.; Perron, M.; Lee, M.; Li, Y.; Song, B.; Javanbakht, H.; Diaz-Griffero, F.; Anderson, D. J.; Sundquist, W. I.; Sodroski, J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5_ restriction factor. Proc. Natl. Acad. Sci. USA 2006, 103, 5514–5519.
60. Stremlau, M.; Owens, C. M.; Perron, M. J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5_ restricts HIV-1 infection in old world monkeys. Nature 2004, 427, 848–853.
61. Kane, M.; Yadav, S. S.; Bitzegeio, J.; Kutluay, S. B.; Zang, T.; Wilson, S. J.; Schoggins, J. W.; Rice, C. M.; Yamashita, M.; Hatziioannou, T.; et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013, 502, 563–566.
62. Goujon, C.; Moncorgé, O.; Bauby, H.; Doyle, T.; Ward, C. C.; Schaller, T.; Hué, S.; Barclay, W. S.; Schulz, R.; Malim, M. H. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 502, 559–562.
63. Schulte, B.; Buffone, C.; Opp, S.; di Nunzio, F.; de Souza Aranha Vieira, D. A.; Brandariz-Nuñez, A.; Diaz-Griffero, F. Restriction of HIV-1 requires the N-terminal region of MxB as a capsid-binding motif but not as a nuclear localization signal. J. Virol. 2015, 89, 8599–8610.
64. Liu, Z.; Pan, Q.; Liang, Z.; Qiao, W.; Cen, S.; Liang, C. The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. Retrovirology 2015, 12, 1.
65. Busnadiego, I.; Kane, M.; Rihn, S. J.; Preugschas, H. F.; Hughes, J.; Blanco-Melo, D.; Strouvelle, V. P.; Zang, T. M.; Willett, B. J.; Boutell, C.; et al. Host and viral determinants of Mx2 antiretroviral activity. J. Virol. 2014, 88, 7738–7752.
66. Matreyek, K. A.; Wang, W.; Serrao, E.; Singh, P. K.; Levin, H. L.; Engelman, A. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology 2014, 11, 90.
67. Laguette, N.; Sobhian, B.; Casartelli, N.; Ringeard, M.; Chable-Bessia, C.; Ségéral, E.; Yatim, A.; Emiliani, S.; Schwartz, O.; Benkirane, M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474, 654–657.
68. Lahouassa, H.; Daddacha, W.; Hofmann, H.; Ayinde, D.; Logue, E. C.; Dragin, L.; Bloch, N.; Maudet, C.; Bertrand, M.; Gramberg, T.; et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 2012, 13, 223–228.
69. Sheehy, A. M.; Gaddis, N. C.; Choi, J. D.; Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418, 646–650.
70. Zhang, H.; Yang, B.; Pomerantz, R. J.; Zhang, C.; Arunachalam, S. C.; Gao, L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424, 94–98.
71. Mangeat, B.; Turelli, P.; Caron, G.; Friedli, M.; Perrin, L.; Trono, D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424, 99–103.
72. Li, M.; Kao, E.; Gao, X.; Sandig, H.; Limmer, K.; Pavon-Eternod, M.; Jones, T. E.; Landry, S.; Pan, T.; Weitzman, M. D.; et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 2012, 491, 125–128.
73. Stabell, A. C.; Hawkins, J.; Li, M.; Gao, X.; David, M.; Press, W. H.; Sawyer, S. L. Non-human primate schlafen11 inhibits production of both host and viral proteins. PLoS Pathog. 2016, 12, e1006066.
74. VanWeringh, A.; Ragonnet-Cronin, M.; Pranckeviciene, E.; Pavon-Eternod, M.; Kleiman, L.; Xia, X. HIV-1 modulates the tRNA pool to improve translation efficiency. Mol. Biol. Evol. 2011, 28, 1827–1834.
75. Neil, S. J. D.; Eastman, S. W.; Jouvenet, N.; Bieniasz, P. D. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2006, 2, e39.
76. Neil, S. J. D.; Zang, T.; Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451, 425–430.
77. Van Damme, N.; Goff, D.; Katsura, C.; Jorgenson, R. L.; Mitchell, R.; Johnson, M. C.; Stephens, E. B.; Guatelli, J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3, 245–252.
78. Tada, T.; Zhang, Y.; Koyama, T.; Tobiume, M.; Tsunetsugu-Yokota, Y.; Yamaoka, S.; Fujita, H.; Tokunaga, K. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat. Med. 2015, 21, 1502–1507.
79. Trautz, B.; Pierini, V.; Wombacher, R.; Stolp, B.; Chase, A. J.; Pizzato, M.; Fackler, O. T. The antagonism of HIV-1 Nef to SERINC5 particle infectivity restriction involves the counteraction of virion-associated pools of the restriction factor. J. Virol. 2016, 90, 10915–10927.
80. Sheehy, A. M.; Gaddis, N. C.; Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9, 1404–1407.
81. Anderson, B. D.; Harris, R. S. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-_/RUNX axis. Sci. Adv. 2015, 1, e1500296.
82. Stopak, K.; de Noronha, C.; Yonemoto, W.; Greene, W. C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12, 591–601.
83. Hrecka, K.; Hao, C.; Gierszewska, M.; Swanson, S. K.; Kesik-Brodacka, M.; Srivastava, S.; Florens, L.; Washburn, M. P.; Skowronski, J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474, 658–661.
84. Lim, E. S.; Fregoso, O. I.; McCoy, C. O.; Matsen, F. A.; Malik, H. S.; Emerman, M. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 2012, 11, 194–204.
85. McNatt, M. W.; Zang, T.; Bieniasz, P. D. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog. 2013, 9, e1003299.
86. Shibata, R.; Sakai, H.; Kawamura, M.; Tokunaga, K.; Adachi, A. Early replication block of human immunodeficiency virus type 1 in monkey cells. J. Gen. Virol. 1995, 76 Pt 11, 2723–2730.
87. Himathongkham, S.; Luciw, P. A. Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology 1996, 219, 485–488.
88. Danielson, C. M.; Cianci, G. C.; Hope, T. J. Recruitment and dynamics of proteasome association with rhTRIM5_ cytoplasmic complexes during HIV-1 infection. Traffic 2012, 13, 1206–1217.
89. Lukic, Z.; Hausmann, S.; Sebastian, S.; Rucci, J.; Sastri, J.; Robia, S. L.; Luban, J.; Campbell, E. M. TRIM5_ associates with proteasomal subunits in cells while in complex with HIV-1 virions. Retrovirology 2011, 8, 93.
90. Rold, C. J.; Aiken, C. Proteasomal degradation of TRIM5_ during retrovirus restriction. PLoS Pathog. 2008, 4, e1000074.
91. Campbell, E. M.; Weingart, J.; Sette, P.; Opp, S.; Sastri, J.; O’Connor, S. K.; Talley, S.; Diaz-Griffero, F.; Hirsch, V.; Bouamr, F. TRIM5_-mediated ubiquitin chain conjugation is required for inhibition of HIV-1 reverse transcription and capsid destabilization. J. Virol. 2015, 90, 1849–1857.
92. Kutluay, S. B.; Perez-Caballero, D.; Bieniasz, P. D. Fates of retroviral core components during unrestricted and TRIM5-restricted infection. PLoS Pathog. 2013, 9, e1003214.
93. Anderson, J. L.; Campbell, E. M.; Wu, X.; Vandegraaff, N.; Engelman, A.; Hope, T. J. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J. Virol. 2006, 80, 9754–9760.
94. Pertel, T.; Hausmann, S.; Morger, D.; Züger, S.; Guerra, J.; Lascano, J.; Reinhard, C.; Santoni, F. A.; Uchil, P. D.; Chatel, L., et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011, 472, 361–365.
95. Yudina, Z.; Roa, A.; Johnson, R.; Biris, N.; de Souza Aranha Vieira, D. A.; Tsiperson, V.; Reszka, N.; Taylor, A. B.; Hart, P. J.; Demeler, B.; et al. RING dimerization links higher-order assembly of TRIM5_ to synthesis of K63-linked polyubiquitin. Cell Rep. 2015, 12, 788–797.
96. Ohmura-Hoshino, M.; Matsuki, Y.; Aoki, M.; Goto, E.; Mito, M.; Uematsu, M.; Kakiuchi, T.; Hotta, H.; Ishido, S. Inhibition of MHC class II expression and immune responses by c-MIR. J. Immunol. 2006, 177, 341–354.
97. Van de Kooij, B.; Verbrugge, I.; de Vries, E.; Gijsen, M.; Montserrat, V.; Maas, C.; Neefjes, J.; Borst, J. Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. J. Biol. Chem. 2013, 288, 6617–6628.
98. Chen, R.; Li, M.; Zhang, Y.; Zhou, Q.; Shu, H. -B. The E3 ubiquitin ligase MARCH8 negatively regulates IL-1_-induced NF-_B activation by targeting the IL1RAP coreceptor for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 2012, 109, 14128–14133.
99. Eyster, C. A.; Cole, N. B.; Petersen, S.; Viswanathan, K.; Früh, K.; Donaldson, J. G. MARCH ubiquitin ligases alter the itinerary of clathrin-independent cargo from recycling to degradation. Mol. Biol. Cell 2011, 22, 3218–3230.
100. Ito, F.; Fu, Y.; Kao, S. -C. A.; Yang, H.; Chen, X. S. Family-wide comparative analysis of cytidine and methylcytidine deamination by eleven human APOBEC proteins. J. Mol. Biol. 2017, 429, 1787–1799.
101. Liddament, M. T.; Brown, W. L.; Schumacher, A. J.; Harris, R. S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 In Vivo. Curr. Biol. 2004, 14, 1385–1391.
102. Harris, R. S.; Bishop, K. N.; Sheehy, A. M.; Craig, H. M.; Petersen-Mahrt, S. K.; Watt, I. N.; Neuberger, M. S.; Malim, M. H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113, 803–809.
103. Yang, B.; Chen, K.; Zhang, C.; Huang, S.; Zhang, H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 2007, 282, 11667–11675.
104. Yu, X.; Yu, Y.; Liu, B.; Luo, K.; Kong, W.; Mao, P.; Yu, X. -F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302, 1056–1060.
105. Mehle, A.; Thomas, E. R.; Rajendran, K. S.; Gabuzda, D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 2006, 281, 17259–17265.
106. Mehle, A.; Goncalves, J.; Santa-Marta, M.; McPike, M.; Gabuzda, D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004, 18, 2861–2866.
107. Valera, M. -S.; de Armas-Rillo, L.; Barroso-González, J.; Ziglio, S.; Batisse, J.; Dubois, N.; Marrero-Hernández, S.; Borel, S.; García-Expósito, L.; Biard-Piechaczyk, M.; et al. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation. Retrovirology 2015, 12.
108. Izumi, T.; Takaori-Kondo, A.; Shirakawa, K.; Higashitsuji, H.; Itoh, K.; Io, K.; Matsui, M.; Iwai, K.; Kondoh, H.; Sato, T.; et al. MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 2009, 6, 1.
109. Matsui, Y.; Shindo, K.; Nagata, K.; Yoshinaga, N.; Shirakawa, K.; Kobayashi, M.; Takaori-Kondo, A. Core binding factor _ protects HIV, type 1 accessory protein viral infectivity factor from MDM2-mediated degradation. J. Biol. Chem. 2016, 291, 24892–24899.
110. Jäger, S.; Kim, D. Y.; Hultquist, J. F.; Shindo, K.; LaRue, R. S.; Kwon, E.; Li, M.; Anderson, B. D.; Yen, L.; Stanley, D.; et al. Vif hijacks CBF-_ to degrade APOBEC3G and promote HIV-1 infection. Nature 2011, 481, 371–375.
111. Zhang, W.; Du, J.; Evans, S. L.; Yu, Y.; Yu, X. -F. T-cell differentiation factor CBF-_ regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2011, 481, 376–379.
112. Mercenne, G.; Bernacchi, S.; Richer, D.; Bec, G.; Henriet, S.; Paillart, J. -C.; Marquet, R. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res. 2010, 38, 633–646.
113. Guerrero, S.; Libre, C.; Batisse, J.; Mercenne, G.; Richer, D.; Laumond, G.; Decoville, T.; Moog, C.; Marquet, R.; Paillart, J. -C. Translational regulation of APOBEC3G mRNA by Vif requires its 5’UTR and contributes to restoring HIV-1 infectivity. Sci. Rep. 2016, 6, 39507.
114. Hultquist, J. F.; Lengyel, J. A.; Refsland, E. W.; LaRue, R. S.; Lackey, L.; Brown, W. L.; Harris, R. S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85, 11220–11234.
115. Binka, M.; Ooms, M.; Steward, M.; Simon, V. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J. Virol. 2012, 86, 49–59.
116. Feng, Y.; Baig, T. T.; Love, R. P.; Chelico, L. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front. Microbiol. 2014, 5, 450.
117. Liu, B.; Sarkis, P. T. N.; Luo, K.; Yu, Y.; Yu, X. -F. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 2005, 79, 9579–9587.
118. Goldstone, D. C.; Ennis-Adeniran, V.; Hedden, J. J.; Groom, H. C. T.; Rice, G. I.; Christodoulou, E.; Walker, P. A.; Kelly, G.; Haire, L. F.; Yap, M. W.; et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011, 480, 379–382.
119. Powell, R. D.; Holland, P. J.; Hollis, T.; Perrino, F. W. Aicardi-goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 2011, 286, 43596–43600.
120. Kim, B.; Nguyen, L. A.; Daddacha, W.; Hollenbaugh, J. A. Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J. Biol. Chem. 2012, 287, 21570–21574.
121. Baldauf, H. -M.; Pan, X.; Erikson, E.; Schmidt, S.; Daddacha, W.; Burggraf, M.; Schenkova, K.; Ambiel, I.; Wabnitz, G.; Gramberg, T.; et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat. Med. 2012, 18, 1682–1687.
122. Bergamaschi, A.; Ayinde, D.; David, A.; le Rouzic, E.; Morel, M.; Collin, G.; Descamps, D.; Damond, F.; Brun-Vezinet, F.; Nisole, S.; et al. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J. Virol. 2009, 83, 4854–4860.
123. Brandariz-Nuñez, A.; Valle-Casuso, J. C.; White, T. E.; Laguette, N.; Benkirane, M.; Brojatsch, J.; Diaz-Griffero, F. Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology 2012, 9, 49.
124. Hofmann, H.; Logue, E. C.; Bloch, N.; Daddacha, W.; Polsky, S. B.; Schultz, M. L.; Kim, B.; Landau, N. R. The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. J. Virol. 2012, 86, 12552–12560.
125. Tan, L.; Ehrlich, E.; Yu, X. -F. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J. Virol. 2007, 81, 10822–10830.
126. Belzile, J. -P.; Duisit, G.; Rougeau, N.; Mercier, J.; Finzi, A.; Cohen, E. A. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog. 2007, 3, e85.
127. Laguette, N.; Brégnard, C.; Hue, P.; Basbous, J.; Yatim, A.; Larroque, M.; Kirchhoff, F.; Constantinou, A.; Sobhian, B.; Benkirane, M. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 2014, 156, 134–145.
128. Zhou, X.; DeLucia, M.; Ahn, J. SLX4-SLX1 protein-independent down-regulation of MUS81-EME1 protein by HIV-1 viral protein R (Vpr). J. Biol. Chem. 2016, 291, 16936–16947.
129. Tristem, M.; Purvis, A.; Quicke, D. L. J. Complex evolutionary history of primate lentiviralvprgenes. Virology 1998, 240, 232–237.
130. Fregoso, O. I.; Ahn, J.; Wang, C.; Mehrens, J.; Skowronski, J.; Emerman, M. Evolutionary toggling of Vpx/Vpr specificity results in divergent recognition of the restriction factor SAMHD1. PLoS Pathog. 2013, 9, e1003496.
131. Pauls, E.; Ruiz, A.; Badia, R.; Permanyer, M.; Gubern, A.; Riveira-Muñoz, E.; Torres-Torronteras, J.; Alvarez, M.; Mothe, B.; Brander, C.; et al. Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. J. Immunol. 2014, 193, 1988–1997.
132. Rocha-Perugini, V.; Suárez, H.; Álvarez, S.; López-Martín, S.; Lenzi, G. M.; Vences-Catalán, F.; Levy, S.; Kim, B.; Muñoz-Fernández, M. A.; Sánchez-Madrid, F.; et al. CD81 association with SAMHD1 enhances HIV-1 reverse transcription by increasing dNTP levels. Nat. Microbiol. 2017.
133. Kyei, G. B.; Cheng, X.; Ramani, R.; Ratner, L. Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. Cell Host Microbe 2015, 17, 98–106.
134. Hinz, A.; Miguet, N.; Natrajan, G.; Usami, Y.; Yamanaka, H.; Renesto, P.; Hartlieb, B.; McCarthy, A. A.; Simorre, J. -P.; Göttlinger, H.; et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 2010, 7, 314–323.
135. Venkatesh, S.; Bieniasz, P. D. Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog. 2013, 9, e1003483.
136. Skasko, M.; Wang, Y.; Tian, Y.; Tokarev, A.; Munguia, J.; Ruiz, A.; Stephens, E. B.; Opella, S. J.; Guatelli, J. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J. Biol. Chem. 2012, 287, 58–67.
137. Mitchell, R. S.; Katsura, C.; Skasko, M. A.; Fitzpatrick, K.; Lau, D.; Ruiz, A.; Stephens, E. B.; Margottin-Goguet, F.; Benarous, R.; Guatelli, J. C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via _-TrCP and endo-lysosomal trafficking. PLoS Pathog. 2009, 5, e1000450.
138. Dubé, M.; Roy, B. B.; Guiot-Guillain, P.; Binette, J.; Mercier, J.; Chiasson, A.; Cohen, E. A. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 2010, 6, e1000856.
139. Roy, N.; Pacini, G.; Berlioz-Torrent, C.; Janvier, K. Characterization of E3 ligases involved in lysosomal sorting of the HIV-1 restriction factor BST2. J. Cell Sci. 2017, 130, 1596–1611.
140. Margottin, F.; Bour, S. P.; Durand, H.; Selig, L.; Benichou, S.; Richard, V.; Thomas, D.; Strebel, K.; Benarous, R. A novel human WD protein, h-_ TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1998, 1, 565–574.
141. Iwabu, Y.; Fujita, H.; Kinomoto, M.; Kaneko, K.; Ishizaka, Y.; Tanaka, Y.; Sata, T.; Tokunaga, K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284, 35060–35072.
142. Douglas, J. L.; Viswanathan, K.; McCarroll, M. N.; Gustin, J. K.; Früh, K.; Moses, A. V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {_}TrCP-dependent mechanism. J. Virol. 2009, 83, 7931–7947.
143. Mangeat, B.; Gers-Huber, G.; Lehmann, M.; Zufferey, M.; Luban, J.; Piguet, V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its _-TrCP2-dependent degradation. PLoS Pathog. 2009, 5, e1000574.
144. Ramirez, P. W.; DePaula-Silva, A. B.; Szaniawski, M.; Barker, E.; Bosque, A.; Planelles, V. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins. Retrovirology 2015, 12, 65.
145. Kueck, T.; Foster, T. L.; Weinelt, J.; Sumner, J. C.; Pickering, S.; Neil, S. J. D. Serine phosphorylation of HIV-1 Vpu and its binding to tetherin regulates interaction with clathrin adaptors. PLoS Pathog. 2015, 11, e1005141.
146. Tervo, H. -M.; Homann, S.; Ambiel, I.; Fritz, J. V.; Fackler, O. T.; Keppler, O. T. _-TrCP is dispensable for Vpu’s ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 2011, 8, 9.
147. Madjo, U.; Leymarie, O.; Frémont, S.; Kuster, A.; Nehlich, M.; Gallois-Montbrun, S.; Janvier, K.; Berlioz-Torrent, C. LC3C contributes to Vpu-mediated antagonism of BST2/Tetherin restriction on HIV-1 release through a non-canonical autophagy pathway. Cell Rep. 2016, 17, 2221–2233.
148. Pujol, F. M.; Laketa, V.; Schmidt, F.; Mukenhirn, M.; Müller, B.; Boulant, S.; Grimm, D.; Keppler, O. T.; Fackler, O. T. HIV-1 Vpu antagonizes CD317/Tetherin by adaptor protein-1-mediated exclusion from virus assembly sites. J. Virol. 2016, 90, 6709–6723.
149. Janvier, K.; Pelchen-Matthews, A.; Renaud, J. -B.; Caillet, M.; Marsh, M.; Berlioz-Torrent, C. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog. 2011, 7, e1001265.
150. Krapp, C.; Hotter, D.; Gawanbacht, A.; McLaren, P. J.; Kluge, S. F.; Stürzel, C. M.; Mack, K.; Reith, E.; Engelhart, S.; Ciuffi, A.; et al. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe 2016, 19, 504–514.
151. McLaren, P. J.; Gawanbacht, A.; Pyndiah, N.; Krapp, C.; Hotter, D.; Kluge, S. F.; Götz, N.; Heilmann, J.; Mack, K.; Sauter, D.; et al. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology 2015, 12, 41.
152. Schubert, U.; Bour, S.; Willey, R. L.; Strebel, K. Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J. Virol. 1999, 73, 887–896.
153. Bour, S.; Schubert, U.; Peden, K.; Strebel, K. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: A Vpu-like factor? J. Virol. 1996, 70, 820–829.
154. Bour, S.; Strebel, K. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J. Virol. 1996, 70, 8285–8300.
155. Zhang, F.; Wilson, S. J.; Landford, W. C.; Virgen, B.; Gregory, D.; Johnson, M. C.; Munch, J.; Kirchhoff, F.; Bieniasz, P. D.; Hatziioannou, T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6, 54–67.
156. Jia, B.; Serra-Moreno, R.; Neidermyer, W.; Rahmberg, A.; Mackey, J.; Fofana, I. B.; Johnson, W. E.; Westmoreland, S.; Evans, D. T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009, 5, e1000429.
157. Sauter, D.; Schindler, M.; Specht, A.; Landford, W. N.; Münch, J.; Kim, K. -A.; Votteler, J.; Schubert, U.; Bibollet-Ruche, F.; Keele, B. F.; et al. The evolution of pandemic and non-pandemic HIV-1 strains has been driven by Tetherin antagonism. Cell Host Microbe 2009, 6, 409–421.
158. Willey, R. L.; Maldarelli, F.; Martin, M. A.; Strebel, K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 1992, 66, 7193–7200.
159. Schubert, U.; Antón, L. C.; Bacík, I.; Cox, J. H.; Bour, S.; Bennink, J. R.; Orlowski, M.; Strebel, K.; Yewdell, J. W. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 1998, 72, 2280–2288.
160. Binette, J.; Dubé, M.; Mercier, J.; Halawani, D.; Latterich, M.; Cohen, E. A. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology 2007, 4, 75.
161. Magadán, J. G.; Pérez-Victoria, F. J.; Sougrat, R.; Ye, Y.; Strebel, K.; Bonifacino, J. S. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 2010, 6, e1000869.
162. Magadán, J. G.; Bonifacino, J. S. Transmembrane domain determinants of CD4 downregulation by HIV-1 Vpu. J. Virol. 2012, 86, 757–772.
163. Petris, G.; Casini, A.; Sasset, L.; Cesaratto, F.; Bestagno, M.; Cereseto, A.; Burrone, O. R. CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules. J. Biol. Chem. 2014, 289, 1–12.
164. Sugden, S. M.; Pham, T. N. Q.; Cohen, É. A. HIV-1 Vpu downmodulates ICAM-1 expression, resulting in decreased killing of infected CD4(+) T cells by NK cells. J. Virol. 2017, 91.
165. Matheson, N. J.; Sumner, J.; Wals, K.; Rapiteanu, R.; Weekes, M. P.; Vigan, R.; Weinelt, J.; Schindler, M.; Antrobus, R.; Costa, A. S. H.; et al. Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef. Cell Host Microbe 2015, 18, 409–423.
166. Ahn, J.; Vu, T.; Novince, Z.; Guerrero-Santoro, J.; Rapic-Otrin, V.; Gronenborn, A. M. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J. Biol. Chem. 2010, 285, 37333–37341.
167. Wu, Y.; Zhou, X.; Barnes, C. O.; DeLucia, M.; Cohen, A. E.; Gronenborn, A. M.; Ahn, J.; Calero, G. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction. Nat. Struct. Mol. Biol. 2016, 23, 933–940.
168. Schröfelbauer, B.; Yu, Q.; Zeitlin, S. G.; Landau, N. R. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 2005, 79, 10978–10987.
169. Zhou, D.; Wang, Y.; Tokunaga, K.; Huang, F.; Sun, B.; Yang, R. The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway. Virus Res. 2015, 195, 25–34.
170. Casey Klockow, L.; Sharifi, H. J.; Wen, X.; Flagg, M.; Furuya, A. K. M.; Nekorchuk, M.; de Noronha, C. M. C. The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology 2013, 444, 191–202.
171. Lahouassa, H.; Blondot, M. -L.; Chauveau, L.; Chougui, G.; Morel, M.; Leduc, M.; Guillonneau, F.; Ramirez, B. C.; Schwartz, O.; Margottin-Goguet, F. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages. Proc. Natl. Acad. Sci. USA 2016, 113, 5311–5316.
172. Romani, B.; Shaykh Baygloo, N.; Aghasadeghi, M. R.; Allahbakhshi, E. HIV-1 Vpr protein Enhances proteasomal degradation of MCM10 DNA replication factor through the Cul4-DDB1[VprBP] E3 ubiquitin ligase to induce G2/M cell cycle arrest. J. Biol. Chem. 2015, 290, 17380–17389.
173. Maudet, C.; Sourisce, A.; Dragin, L.; Lahouassa, H.; Rain, J. -C.; Bouaziz, S.; Ramirez, B. C.; Margottin-Goguet, F. HIV-1 Vpr induces the degradation of ZIP and sZIP, adaptors of the NuRD chromatin remodeling complex, by hijacking DCAF1/VprBP. PLoS ONE 2013, 8, e77320.
174. Romani, B.; Baygloo, N. S.; Hamidi-Fard, M.; Aghasadeghi, M. R.; Allahbakhshi, E. HIV-1 Vpr protein induces proteasomal degradation of chromatin-associated class I HDACs to overcome latent infection of macrophages. J. Biol. Chem. 2016, 291, 2696–2711.
175. Klinger, P. P.; Schubert, U. The ubiquitin-proteasome system in HIV replication: Potential targets for antiretroviral therapy. Expert Rev. Anti-Infect. Ther. 2005, 3, 61–79.
176. Wang, H.; Guo, H.; Su, J.; Rui, Y.; Zheng, W.; Gao, W.; Zhang, W.; Li, Z.; Liu, G.; Markham, R. B.; et al. Inhibition of Vpx-mediated SAMHD1 and Vpr-mediated host helicase transcription factor degradation by selective disruption of viral CRL4 (DCAF1) E3 ubiquitin ligase assembly. J. Virol. 2017, 91.